Transplant Rejection Prevention

Over 40,000 organ transplants performed annually in the U.S.; 200,000+ transplant recipients on active immunosuppression·6 treatments

After organ transplantation (kidney, liver, heart, lung), the immune system recognizes the new organ as foreign and attacks it. Immunosuppressive medications are essential to prevent rejection and protect the transplanted organ. Missing even a few doses can trigger rejection and organ loss. Lifelong immunosuppression is required for most transplant recipients.

You may qualify for clinical trials that provide Prograf at no cost

Clinical trials may give you access to this treatment while helping advance medical research

Search Trials

Prograforal CellCeptoral Nulojixinfusion Envarsus XRoral Zortressoral Imuranoral

Standard immunosuppression regimens typically include a calcineurin inhibitor (tacrolimus/Prograf), an antimetabolite (mycophenolate/CellCept), and corticosteroids. Brand-name tacrolimus may be required if generic substitution causes therapeutic level fluctuations. Belatacept (Nulojix) requires documented calcineurin inhibitor intolerance or contraindication.

Generic immunosuppressant required before brand-name formulation

Very Common

Narrow therapeutic index drug switched without physician approval

Common

Belatacept (Nulojix) denied — must fail standard calcineurin inhibitor regimen

Common

Dose or formulation change denied without updated transplant center documentation

Occasional

Prior authorization lapse causing gap in immunosuppression coverage

Occasional

1.Document transplant type, date, and current transplant center follow-up
2.For brand vs. generic disputes, include tacrolimus trough levels showing variability with generic
3.Emphasize that immunosuppression gaps risk irreversible organ rejection — this is time-sensitive
4.Include transplant center letter supporting the specific regimen requested
5.Cite KDIGO or ISHLT guidelines for organ-specific immunosuppression protocols